Composition comprising and method of using angiopoietin-like protein 3 Angptl3
AssigneeGenentech, Inc.
InventorsNapoleone Ferrara, Hans-Peter Gerber, Joe Kowalski, Maria Teresa Pisabarro, Daniel Eric Sherman
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.
Claims75
A method of treating tissue damage characterized by overexpression of Angptl3, comprising treating the tissue with an antagonist of Angptl3.
A method for the treatment of a chronic liver disease in a mammalian subject, comprising administering to a mammalian subject in need an effective amount of an antagonist of Angptl3.
A method for the treatment of a heart disease characterized by the elevated expression of Angptl3 in a mammalian subject, comprising administering to the subject an effective amount of an antagonist of Angptl3.
A method for the treatment of acute liver disease, comprising administering to a mammalian subject in need a therapeutically effective amount of a polypeptide comprising an amino acid sequence having at least 80% sequence identity to the human Angptl3 sequence of SEQ ID NO:
- 2, or an agonist thereof.
A method of inducing liver regeneration following acute liver injury, comprising administering to a mammalian subject in need a therapeutically effective amount of a polypeptide comprising an amino acid sequence having at least 80% sequence identity to the human Angptl3 sequence of SEQ ID NO:
- 2, or an agonist thereof.
A method for inducing angiogenesis in a tissue comprising treating the tissue with an effective amount of a polypeptide comprising an amino acid sequence having at least 80% sequence identity to the human Angptl3 sequence of SEQ ID NO:
- 2, or an agonist thereof.
A method for inhibiting an undesired increase in vascular permeability in a tissue comprising treating the tissue with an effective amount of an antagonist of Angptl3.
A method for identifying a human subject at risk of cardiovascular disease, comprising determining the level of Angptl3 mRNA or its expression product in the heart tissue of said subject, relative to the level of Angptl3 or its expression product in normal heart tissue, and identifying the subject as being at risk if the level of Angptl3 mRNA or its expression product in the heart tissue of the subject is elevated relative to the normal heart tissue.
A method for identifying a human subject at risk of liver damage, comprising determining the level of Angptl3 mRNA or its expression product in the liver tissue of said subject, relative to the level of Angptl3 or its expression product in normal liver tissue, and identifying the subject as being at risk if the level of Angptl3 mRNA or its expression product in the liver tissue of the subject is elevated relative to the normal liver tissue.
Dependencies are inferred from the claim text.